These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 9527138)

  • 1. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.
    Andreasen N; Vanmechelen E; Van de Voorde A; Davidsson P; Hesse C; Tarvonen S; Räihä I; Sourander L; Winblad B; Blennow K
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):298-305. PubMed ID: 9527138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.
    Andreasen N; Hesse C; Davidsson P; Minthon L; Wallin A; Winblad B; Vanderstichele H; Vanmechelen E; Blennow K
    Arch Neurol; 1999 Jun; 56(6):673-80. PubMed ID: 10369305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.
    Skoog I; Vanmechelen E; Andreasson LA; Palmertz B; Davidsson P; Hesse C; Blennow K
    Neurodegeneration; 1995 Dec; 4(4):433-42. PubMed ID: 8846237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.
    Arai H; Satoh-Nakagawa T; Higuchi M; Morikawa Y; Miura M; Kawakami H; Seki H; Takase S; Sasaki H
    Neurosci Lett; 1998 Nov; 256(3):174-6. PubMed ID: 9855368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.
    Andreasen N; Minthon L; Clarberg A; Davidsson P; Gottfries J; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
    Neurology; 1999 Oct; 53(7):1488-94. PubMed ID: 10534256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau protein in cerebrospinal fluid from semantic dementia patients.
    Andersen C; Froelich Fabre S; Ostberg P; Lannfelt L; Wahlund L
    Neurosci Lett; 2000 Nov; 294(3):155-8. PubMed ID: 11072138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.
    Arai H; Higuchi S; Sasaki H
    Gerontology; 1997; 43 Suppl 1():2-10. PubMed ID: 9187933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia.
    Leszek J; Małyszczak K; Janicka B; Kiejna A; Wiak A
    Med Sci Monit; 2003 Nov; 9(11):CR484-8. PubMed ID: 14586274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
    Engelborghs S; Le Bastard N
    J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias.
    Molina L; Touchon J; Herpé M; Lefranc D; Duplan L; Cristol JP; Sabatier R; Vermersch P; Pau B; Mourton-Gilles C
    Neuroreport; 1999 Nov; 10(17):3491-5. PubMed ID: 10619631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.
    Kanai M; Shizuka M; Urakami K; Matsubara E; Harigaya Y; Okamoto K; Shoji M
    Neurosci Lett; 1999 May; 267(1):65-8. PubMed ID: 10400250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.
    Sjögren M; Blomberg M; Jonsson M; Wahlund LO; Edman A; Lind K; Rosengren L; Blennow K; Wallin A
    J Neurosci Res; 2001 Nov; 66(3):510-6. PubMed ID: 11746370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.
    Grangeon L; Paquet C; Bombois S; Quillard-Muraine M; Martinaud O; Bourre B; Lefaucheur R; Nicolas G; Dumurgier J; Gerardin E; Jan M; Laplanche JL; Peoc'h K; Hugon J; Pasquier F; Maltête D; Hannequin D; Wallon D;
    J Alzheimers Dis; 2016; 51(3):905-13. PubMed ID: 26890785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias.
    Amadoro G; Corsetti V; Sancesario GM; Lubrano A; Melchiorri G; Bernardini S; Calissano P; Sancesario G
    J Alzheimers Dis; 2014; 42(1):211-26. PubMed ID: 24851856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.